1 – 10 of 14
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases
(
- Contribution to journal › Article
-
Mark
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
(
- Contribution to journal › Article
- 2023
-
Mark
Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction Are Altered in Parkinson's Disease and Related Disorders
(
- Contribution to journal › Article
- 2022
-
Mark
Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum
(
- Contribution to journal › Article
- 2021
-
Mark
Neuroligin-1 in brain and CSF of neurodegenerative disorders : investigation for synaptic biomarkers
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
(
- Contribution to journal › Article
- 2019
-
Mark
Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Novel tau fragments in cerebrospinal fluid : relation to tangle pathology and cognitive decline in Alzheimer’s disease
(
- Contribution to journal › Article
- 2017
-
Mark
Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
(
- Contribution to journal › Article
-
Mark
A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease
(
- Contribution to journal › Article